ArticleThe Korean journal of internal medicine2024
Korean treatment recommendations for patients with axial spondyloarthritis.
Article in The Korean journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial.Rheumatology and immunology research · 2026Article
- Saudi Clinical Practice Guidelines for Management of Axial Spondyloarthritis Disease.Rheumatology and therapy · 2025Article
- Metabolic musculoskeletal disorders in patients with inflammatory bowel disease.The Korean journal of internal medicine · 2025Review
- Case Report: Long-term improvement after acupotomy in advanced ankylosing spondylitis with sacroiliac joint fusion.Frontiers in surgery · 2025Article
Corrections and comments
- Erratum for
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.